linjc16/ctgov huggingface dataset:
Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

Study Overview
=================
Brief Summary
-----------------
A retrospective analysis of medical records at Far Eastern Memorial Hospital from January 2008 to May 2020 about female patients with overactive bladder syndrome, who received Solifenacin or Mirabegron as the initial treatment. Factors affecting persistence of OAB medications will be analyzed.

Official Title
-----------------
Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

Conditions
-----------------
Overactive Bladder Syndrome

Intervention / Treatment
-----------------
* Drug: Solifenacin Oral Tablet
* Drug: Mirabegron 25mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with overactive bladder syndrome received solifenacin or mirabegron as the initial treatment Exclusion Criteria: <20 year-old

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| solifenacin<br> | Drug: Solifenacin Oral Tablet<br>* Solifenacin 1 tablet per day<br>|
| mirabegron<br> | Drug: Mirabegron 25mg<br>* Mirabegron 1 tablet per day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Predictors of persistence of mirabegron versus solifenacin use |  | 13 years |
Using Breath Metabolites to Determine Specific Virus Infection in Asthmatic Patients

Study Overview
=================
Brief Summary
-----------------
Respiratory virus infections cause a majority of asthma exacerbations in the fall to spring months. Current diagnostic platforms for respiratory viruses have limitations including cost, availability, and invasiveness. The use of noninvasive breath collection to analyze breath metabolites may be used to differentiate virus-infected asthmatics from other causes of acute asthma exacerbations.

Official Title
-----------------
Using Breath Metabolites to Determine Specific Virus Infection in Asthmatic Patients

Conditions
-----------------
Upper Respiratory Tract Infections, Asthma, Exhaled Breath

Intervention / Treatment
-----------------
* Diagnostic Test: Exhaled breath condensate collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Asthma, Age ≥12, Symptoms/signs of an early asthma exacerbation, Ability to provide exhaled breath condensate (EBC) x15 min, Body mass index (BMI) ≥18 Exclusion Criteria: Chronic lung diseases other than asthma (e.g., chronic obstructive pulmonary disease [COPD], lung cancer, fibrotic lung disease, etc.), Smoking in the past 7 days, Eating or non-clear liquids <4 hrs prior to EBC collection, Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy asthma<br>Asthmatic patients not with an exacerbation, i.e., stable asthmatics | Diagnostic Test: Exhaled breath condensate collection<br>* Breath from humans is cooled, condensed, and collected<br>|
| Rhinovirus-infected asthmatics<br>Asthmatics with an exacerbation and associated rhinovirus infection | Diagnostic Test: Exhaled breath condensate collection<br>* Breath from humans is cooled, condensed, and collected<br>|
| Influenza A-infected asthmatics<br>Asthmatics with an exacerbation and associated influenza A infection | Diagnostic Test: Exhaled breath condensate collection<br>* Breath from humans is cooled, condensed, and collected<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Breath metabolite differences between groups | Metabolites from breath will be identified and quantified using gas chromatography-mass spectrometry; these will be compared between groups. Specific breath metabolites include isoprostane, linear and branched alkanes (C6-C9), alcohols, and thiol-containing moieties. However, we will also measure metabolites in an un-targeted manner. | 36 months |
Trial of Chinese Prescription on Ulcerative Colitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of the Chinese prescription on Ulcerative Colitis.

Conditions
-----------------
Ulcerative Colitis

Intervention / Treatment
-----------------
* Drug: bascial prescription plus or minus herbs depend on symptoms


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of ulcerative colitis Male of female patients between 18-65 years old Written informed consent Exclusion Criteria: Combine with malignant pathology on epithelial dysplasia of mucosa Combined with severe heart, gallbladder, kidney, endocrine system, hemopoietic system or nervous system disease. Pregnancy or breast feeding women, or unwilling to have contraception.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: bascial prescription<br>Decoction ,two times a day,one bag of decoction one time | Drug: bascial prescription plus or minus herbs depend on symptoms<br>* Decoction ,two times a day<br>|
| Placebo Comparator: low does of bascial decoction<br>Decoction ,two times a day, one bag decoction of one time | Drug: bascial prescription plus or minus herbs depend on symptoms<br>* Decoction ,two times a day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Histopathological examination,enteroscopy,blood test,symptoms ,pulse tracings,tongue demonstration |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Indicates of liver and renal function |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
alternative medicine, traditional Chinese medicine
The Effect of Snacks on Glycaemic Regulation in Children

Study Overview
=================
Brief Summary
-----------------
Dairy products have a potential to be healthy snack foods for children. The purpose of this project is to investigate the short-term effects of Greek yogurt, a new popular dairy product on the regulation of glucose homeostasis, satiety and energy intake in normal weight and overweight/obese children.

Official Title
-----------------
The Effect of Dairy and Non-Dairy Products on Blood Glucose Regulation in Children

Conditions
-----------------
Blood Glucose, Energy Intake

Intervention / Treatment
-----------------
* Other: dietary treatments


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The children must be born at full-term within the normal weight range Exclusion Criteria: food sensitivities or allergies, dietary restrictions, health, learning, emotional or behavioural problems, of if children are receiving medication

Ages Eligible for Study
-----------------
Minimum Age: 9 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Greek yogurt<br>25 g available carbohydrates | Other: dietary treatments<br>* commercially available food products<br>|
| Experimental: Cookies<br>25 g available carbohydrates | Other: dietary treatments<br>* commercially available food products<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood glucose | concentration of blood glucose | 120 min | 
| insulin | concentration of circulating insulin | 120 min | 
| C-peptide | concentration of circulating C-peptide | 120 min | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Food intake (grams and kcal) | ad libitum food intake at 120 min measured with a test meal (grams consumed converted to kilocalories). | 120 min | 
| Subjective appetite | Four patterns of subjective appetite were measured using 100 mm visual analogue scale (VAS): desire to eat, hunger, fullness, and prospective food consumption at 0 min (immediately before the snack), 15, 30, 45, 60, 90, and immediately before the test meal at 120 min. The average appetite was calculated. | 0-120 min |
Intranasal Insulin for COVID-19-related Smell Loss

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to quantify the improvement in olfaction of 27 post-COVID-19 patients, after three intreventions of intranasal insulin during a four week period, with the help of the Threshold, Discrimination and Identification (TDI) score evaluated with Sniffin Sticks®.

Official Title
-----------------
Intranasal Insulin for COVID-19-related Smell Loss

Conditions
-----------------
Smell Loss, Paraosmia, Hyposmia, Anosmia, COVID-19

Intervention / Treatment
-----------------
* Drug: Insulin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COVID-19 in the last 3 to 18 months and who persisted with anosmia, hyposmia or other olfactory dysfunction chronically and without improvement Exclusion Criteria: nasal tumors, chronic sinusitis, drug-induced sinusitis, nasal polyposis, neurodegenerative disease, smoking, pregnancy Hypoglycemia and a previous diagnosis of diabetes mellitus or anatomical malformations such as septal deviation, rhinosinusitis or choanal atresia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 59 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: intranasal insulin<br>For each selected participant (n=27), a baseline olfactory measurement was performed with Sniffin Sticks® (12 items) and a capillary glucose measurement was obtained with Dextrostix® NF before and after the intervention, in order to guarantee patient safety and reduce the risk of hypoglycemia. The initial and final measurements were divided into three subsections with a different number of correct answers for each section Subsequently, Gelfoam® cottonoids soaked in 40 IU of NPH insulin were placed on the nasal roof (between the nasal septum and the middle meatus) of each nostril. These remained in place for 15 minutes and were later removed. This procedure was performed in three visits one week apart. During the fourth and last visit (one week after the previous visit), olfaction was reevaluated using the measures previously described. | Drug: Insulin<br>* Gelfoam® cottonoids soaked in 40 IU of NPH insulin were placed on the nasal roof (between the nasal septum and the middle meatus) of each nostril. These remained in place for 15 minutes and were later removed. This procedure was performed in three visits one week apart. During the fourth and last visit (one week after the previous visit), olfaction was reevaluated using the measures previously described.<br>* Other names: intranasal insulin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SMELL LOSS IMPROVEMENT |  | 1 MONTH |
Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)

Study Overview
=================
Brief Summary
-----------------
This study will test whether XAF5 (XOPH5) ointment, applied once daily to the lower eyelids for 10 weeks, reduces the prominence of lower eyelid fat in adults with moderate to severe steatoblepharon (excess eyelid fat).

Official Title
-----------------
A Phase 2, Randomized, Double-masked, Placebo-controlled Study of XOPH5 Ointment for Reduction of Lower Lid Steatoblepharon

Conditions
-----------------
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)

Intervention / Treatment
-----------------
* Drug: XOPH5 Ointment
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria (abbreviated): Moderate to severe lower eyelid steatoblepharon (LESS score of 2-4 bilaterally) Men and women 40-70 years old Healthy facial skin Must understand and provide informed consent Exclusion Criteria (abbreviated): Best corrected visual acuity worse than 20/40 in either eye Regular use of ophthalmic medication in either eye Planned use of contact lenses during the study Any history of lower eyelid surgery

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: XOPH5 Ointment<br>XOPH5 Ointment is the investigational drug to be studied. | Drug: XOPH5 Ointment<br> <br> |
| Placebo Comparator: Placebo Ointment<br>Placebo is an ointment that matches XOPH5 Ointment but lacks the active ingredient. | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lower Eyelid Steatoblepharon Severity (LESS) Score--Clinician-Reported | Photonumeric scale, range 0-4, 0 is absence of steatoblepharon, 4 is very severe steatoblepharon. | 11 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
steatoblepharon, blepharoptosis, dermatochalasis, blepharoplasty, periorbital, orbital, eyelid, eyebags, eye bags
Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning

Study Overview
=================
Brief Summary
-----------------
Application Management Team: PI - Siu Wai Choi; email - htswchoi@hku.hk Delegates - Chui Shan Chu; email: sunshine.c@connect.hku.hk FollowUpUsers - Chui Shan Chu; email:sunshine.c@connect.hku.hk

Detailed Description
-----------------
Eligibility Criteria: - patients were diagnosed with a baseline disease of oral squamous carcinoma. Exclusion Criteria: - N/A Sample size: -  500 subjects Source of Data: - The data, such as age and medical records, would be obtained from Hospital Authority Clinical Management System (HACMS) Statistical analysis: - machine learning will be applied into analysis plan

Official Title
-----------------
Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning

Conditions
-----------------
Oral Squamous Cell Carcinoma

Intervention / Treatment
-----------------
* Procedure: Surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with oral squamous carcinoma received surgery from 1st October 2000 to 1st October 2019 Exclusion Criteria: N/A
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with Progressive Disease<br>Patients with metastasis and/or recurrent OSCC were considered as a group of subjects with progressive disease | Procedure: Surgery<br>* Resection of tumors<br>* Other names: Chemo-radiotherapy;|
| Patients without Progressive Disease<br>Patients without metastasis and/or recurrent OSCC were considered as a group of subjects without progressive disease | Procedure: Surgery<br>* Resection of tumors<br>* Other names: Chemo-radiotherapy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcomes of the study are metastasis and recurrent disease | These outcomes will be entered as the dependent variables into the machine learning model | Baseline of OSCC | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
OSCC; Oral cancer; Machine Learning
Primary Hyperoxaluria Mutation Genotyping

Study Overview
=================
Brief Summary
-----------------
This study will help us determine whether certain genetic mutations, more than others, are a cause of more severe disease in Primary Hyperoxaluria.

Detailed Description
-----------------
During your study visit, we will draw one tube, about two teaspoonfuls (1 to 1 ½ teaspoons for children), of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic testing. We will use the isolated DNA to try to identify the gene that is defective in Primary Hyperoxaluria by comparing it with the structure of genes in normal individuals, patients with Primary Hyperoxaluria, and family members of Primary Hyperoxaluria patients. In family members of primary hyperoxaluria patients, a 24 hour urine test may also be collected.

Official Title
-----------------
Correlation of Disease Expression With Specific Genetic Mutations in Primary Hyperoxaluria

Conditions
-----------------
Primary Hyperoxaluria

Intervention / Treatment
-----------------
* Genetic: Genetic Analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: You have been diagnosed, or you are in the process of being diagnosed Primary Hyperoxaluria You have a family member diagnosed with Primary Hyperoxaluria
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Genetic Analysis | Genetic: Genetic Analysis<br>* We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic testing.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine whether certain genetic mutations, more than others, are a cause of more severe disease in Primary Hyperoxaluria |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PH, PH type I, Primary Hyperoxaluria, Hyperoxaluria, Primary Oxalosis, PH type II, PH type III, Genetic testing for PH, Genetic testing for Primary Hyperoxaluria, Hereditary study for PH, Hereditary study for Primary Hyperoxaluria
Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer

Study Overview
=================
Brief Summary
-----------------
Proton Pump Inhibitors (PPI) can prevent the recurrence of peptic ulcer in clopidogrel users.

Detailed Description
-----------------
The aim of the prospective, randomized study is to investigate the efficacy of PPI in prevention of ulcer recurrence for clopidogrel users. We plan to enroll 300 clopidogrel users without baseline gastroduodenal ulcer at initial endoscopy. The patients will be randomly assigned to receive either (1) esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel treatment alone for 6 months. The ulcer recurrence rate between the treatment groups will be compared.

Official Title
-----------------
Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer and Gastrointestinal Bleeding

Conditions
-----------------
Peptic Ulcer

Intervention / Treatment
-----------------
* Drug: esomeprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: We plan to enroll 300 clopidogrel users without baseline gastroduodenal ulcer at initial endoscopy. The patients will be randomly assigned to receive either (1) esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel treatment alone for 6 months. Exclusion Criteria: 1.serious disease 2.refuse informed consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Esomeprazole plus clopidogrel group<br>esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months | Drug: esomeprazole<br>* esomeprazole 20 mg qd for 6 months<br>* Other names: plavix;|
| No Intervention: Clopidogrel group<br>clopidogrel 75 mg qd for 6 months | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrent Peptic Ulcer | Number of participants with recurrent peptic ulcer within 6 months | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peptic Ulcer Bleeding | participants with peptic ulcer bleeding within 6 months | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
proton pump inhibitor, peptic ulcer, clopidogrel, prevention